|
| Study | Number of
patients | CTCs enrichment method | Markers | Stage of disease | Treatment |
|
| Danila et al. [88] (2007) | 120 | CellSearch | CD45− CK+ | CRPC | Chemotherapy |
| de Bono et al. [89] (2008) | 231 | CellSearch | CD45− CK+ | CRPC | Chemotherapy |
| Goodman Jr. et al. [90] (2009) | 100 | CellSearch | CD45− CK+ | CRPC | Chemotherapy |
| Scher et al. [91] (2009) | 156 | CellSearch | CD45− CK+ | CRPC | Surgery/chemotherapy |
| Olmos et al. [92] (2009) | 119 | CellSearch | CD45− CK+ | CRPC | Chemotherapy |
| Joung et al. [93] (2010) | 103 | Nested RT-PCR | PSCA-mRNA+ | High-risk PC | Radical prostatectomy |
| Coumans et al. [94] (2010) | 179 | CellSearch | EpCAM+ CD45− CK+
| CRPC | Chemotherapy |
| Joung et al. [95] (2010) | 134 | Nested RT-PCR | PSMA mRNA+ | Localized PC | Radical prostatectomy |
| Strijobs et al. [96] (2010) | 154 | CellSearch | CD45− CK+ | CRPC | Docetaxel based chemotherapy |
| Danila et al. [97] (2011) | 48 | CellSearch | CD45− CK+ | CRPC | Abiraterone |
| Scher et al. [98] (2013) | 144 | CellSearch | CD45− CK+ | CRPC | Cabozantinib |
| Thalgott et al. [99] (2013) | 55 | CellSearch | CD45− CK+ | CRPC | Docetaxel based chemotherapy |
| Okegawa et al. [100] (2014) | 57 | CellSearch | CD45− CK+ | CRPC | Docetaxel based chemotherapy |
| Danila et al. [101] (2014) | 97 | RT-PCR assay | Not reported | CRPC | Not reported |
| Goldkorn et al. [102] (2014) | 263 | CellSearch | CD45− CK+ | CRPC | Docetaxel based chemotherapy |
| Antonarakis et al. [103] (2014) | 62 | AdnaTest | PSA+ PSMA+or EGFR+ | CRPC | Enzalutamide and abiraterone |
| Chang et al. [104] (2015) | 70 | CellSearch | Not reported | CRPC | Docetaxel based chemotherapy |
| Scher et al. [105] (2015) | 711 | CellSearch | CD45− CK+ | CRPC | Abiraterone or prednisone |
| Fleisher et al. [106] (2015) | 258 | CellSearch | EpCAM+ CD45− CK+ | CRPC | Enzalutamide |
| Thalgott et al. [107] (2015) | 33 | CellSearch | EpCAM+ CK+ nucleic acid+ | CRPC | Docetaxel based chemotherapy |
| Lorente et al. [108] (2015) | 439 | CellSearch | CD45− CK+ | CRPC | Abiraterone or
chemotherapy |
| Crespo et al. [109] (2015) | 48 | CellSearch | CD45− CK+ | CRPC | Enzalutamide and abiraterone |
| Onstenk et al. [110] (2015) | 29 | CellSearch | CD45− CK+ | CRPC | Cabazitaxel based chemotherapy |
| Antonarakis et al. [111] (2015) | 37 | AdnaTest | PSA+ PSMA+ or EGFR+ | CRPC | Chemotherapy |
| Bitting et al. [112] (2015) | 89 | CellSearch | CD45− CK+ | CRPC | Chemotherapy |
| Lorente et al. [113] (2016) | 486 | CellSearch | CD45− CK+ | CRPC | Abiraterone plus prednisone or prednisone |
| Vogelzang et al. [114] (2017) | 208 | CellSearch | CD45− CK+ | CRPC | Docetaxel based chemotherapy |
| Tsumura et al. [115] (2017) | 59 | CellSearch | DAPI+ CK+ CD45− | Nonmetastatic PC | Brachytherapy |
|
